Modern approach to combination therapy in patients with pelvic inflammatory diseases

Objective. The aim of the study was to compare the efficiency of complex therapy of pelvic inflammatory diseases (PID) in patients using the drug Longidaza® and the effectiveness of therapy without the use of this drug. Materials and methods. 150 patients of reproductive age with PID. All women underwent basic therapy. The complex treatment of group 1 included the additional drug Longidaza® in vaginal suppositories 3000 IU with the general course of 20 injections once every three days. The patients were observed for 60 days. The effectiveness of therapy was determined by the dynamics of diagnostic criteria (clinical and laboratory). Results. During the follow-up period, among patients receiving complex therapy with Longidaza® relief of pain syndrome in the lower abdomen was observed much faster, and only 14 (18,5 %) women of group 1 continued to fill it after 2 months of treatment, where as in group 2 – 60 (81,1 %) patients (p < 0,001). Reduction of pain in palpation and cervical traction in patients of the main group was recorded in all (100 %) patients, while in the group of basic therapy this symptom continued to be observed in 23 % of women (p < 0.001). The dynamics of decrease in the share of patients with increased uterine size in group 1 was 14.9 % and in group 2 – only 8.4 % (p < 0.001). In the experimental group, during the 2-month follow-up period, there was observed an increase in the number of patients with a normal number of leukocytes in the vaginal smear by 13 %, while in the second group this parameter increased by only 3 % to the initial value. Conclusions. The results of the research allow indicating the efficiency of treatment of PID when using the drug Longidaza®.